Search Results - therapeutics+%3e+metabolism+and+endocrinology

28 Results

Sort By:

AAV-Based Treatment of Guanidinoacetate Methyltransferase (GAMT) Deficiency (UCLA Case No. 2021-012)

SUMMARY: UCLA researchers in the Departments Molecular & Medical Pharmacology and Surgery in the David Geffen School of Medicine have developed a novel and tissue-specific gene therapy treatment for Guanidinoacetate methyltransferase (GAMT) deficiency. BACKGROUND: Guanidinoacetate Methyltransferase (GAMT) deficiency is caused by a mutation in...

Published: 8/10/2023 | Inventor(s): Gerald Lipshutz

Keywords(s): Adeno-associated viruses (AAV), Creatine, GAMT deficiency, Gene Therapy, Metabolic Diseases

Category(s): Therapeutics > Gene Therapy And Editing, Therapeutics > Genetic Diseases, Therapeutics > Metabolism And Endocrinology

2022-088 Neural Networks for Adipose Tissue Segmentation on Magnetic Resonance Images

Summary: UCLA researchers in the Department of Radiological Sciences have developed a novel neural network that can segment and quantify visceral and subcutaneous adipose tissues on magnetic resonance images automatically, accurately, and rapidly, to enhance clinical methods for characterizing and monitoring risk for cardiometabolic diseases in patients...

Published: 1/17/2024 | Inventor(s): Holden Wu, Sevgi Gokce Kafali-Tekat

Keywords(s): Advanced Computing / AI, Artificial Neural Network, Artificial Neural Network Artificial Neuron, cardiometabolic disease, Hypertension, Imaging, Machine Learning, Magnetic Resonance Imaging, Magnetic Resonance Imaging Pathology, Medical Imaging, MRI, multi-contrast imaging, obesity, Tissue (Biology), tissue annotation, tissue detection, tissue ribbons alignment, tissue segmentation

Category(s): Medical Devices > Medical Imaging, Platforms > Diagnostic Platform Technologies, Medical Devices > Medical Imaging > MRI, Therapeutics > Metabolism And Endocrinology

2020-129 COMPOUNDS FOR TREATING FOOD ADDICTION IN OBESITY

SUMMARYResearchers in the Department of Medicine within the Division of Digestive Diseases at UCLA have identified a set of gut bacteria and gut metabolites as a biomarker for food addiction in obese patients. BACKGROUNDObesity and its comorbidities pose a serious global health crisis. In 2016, about 2 billion adults, 18 years and older, were overweight....

Published: 9/5/2023 | Inventor(s): Arpana Gupta, Tien Dong, Emeran Mayer

Keywords(s):

Category(s): Therapeutics, Therapeutics > Metabolism And Endocrinology

2020-404 IDENTIFICATION OF NOVEL BIOMARKERS FOR NON-ALCOHOLIC FATTY LIVER DISEASE

SUMMARY: UCLA Researchers in the department of medicine have discovered distinct protein signatures in the blood of patients with non-alcoholic fatty liver disease (NAFLD) as well as NAFLD-related traits including steatosis, hepatocellular ballooning, and non-alcoholic steatohepatitis (NASH). These proteins were identified using the next-generation...

Published: 9/5/2023 | Inventor(s): Adriana Huertas Vazquez, Aldons Lusis

Keywords(s):

Category(s): Diagnostic Markers > Targets And Assays, Therapeutics > Metabolism And Endocrinology

2021-116 INJECTABLE BIODEGRADABLE POLYMERIC COMPLEX FOR GLUCOSE-RESPONSIVE INSULIN DELIVERY

Summary: UCLA researchers in the department of Bioengineering have developed a biodegradable material that is capable of releasing insulin in the presence of excess glucose mimicking the insulin secretion properties of pancreatic B-cells as a treatment for Diabetes Mellitus.Background: Diabetes mellitus currently affects more than 463 million people...

Published: 9/5/2023 | Inventor(s): Zhen Gu

Keywords(s):

Category(s): Platforms > Drug Delivery > Other Polymers, Therapeutics > Inflammation And Inflammatory Diseases, Therapeutics > Metabolism And Endocrinology

2020-854 DUAL SELF-REGULATED DELIVERY OF INSULIN AND GLUCAGON BY A HYBRID PATCH

UCLA researchers have developed a novel hybrid microneedle patch that can deliver insulin and glucagon in a glucose-dependent manner. BACKGROUND: Type I diabetes (T1D) is an autoimmune disease in which pancreatic -cells are destroyed and there is a deficiency is insulin secretion. Type 2 diabetes (T2D) is a metabolic disorder resulting from insulin...

Published: 7/19/2023 | Inventor(s): Zhen Gu

Keywords(s): Drug Delivery, Medical Devices and Materials, Metabolic Diseases, Other Polymers, Polymers, Therapeutics & Vaccines

Category(s): Medical Devices, Platforms > Drug Delivery, Therapeutics, Platforms > Drug Delivery > Other Polymers, Therapeutics > Metabolism And Endocrinology

2017-502 Novel Targets and Use of Small Molecule BT-2 to Treat Heart Failure, Obesity and Diabetes

Novel Targets And Use Of Small Molecule BT-2 To Treat Heart Failure, Obesity And DiabetesSUMMARYUCLA researchers from the Cardiovascular Theme in the Departments of Anesthesiology, Physiology and Medicine have discovered new pathways and potential treatment options for heart failure, obesity, and diabetesBACKGROUNDHeart failure is a leading cause of...

Published: 7/19/2023 | Inventor(s): Yibin Wang, Haipeng Sun

Keywords(s): Cardiovascular, Endocrinology, Metabolic Diseases

Category(s): Therapeutics > Cardiovascular, Therapeutics > Metabolism And Endocrinology

2019-623 USE OF A NATURAL METABOLITE AS A CANCER THERAPY

UCLA Researchers in the Department of Chemistry and Biochemistry have devised a novel off label usage for the commonly available supplement s-adenylmethionine in the treatment of cancer.BACKGROUND: Tumor cells exhibit a wildly different metabolism from the tissue they are derived from. This altered metabolism allows sustained proliferation rates while...

Published: 7/19/2023 | Inventor(s): Steven Clarke

Keywords(s): Metabolic Diseases, Oncology, Therapeutics & Vaccines

Category(s): Therapeutics > Oncology, Therapeutics > Metabolism And Endocrinology

2011-417 Small Molecule Inhibitor of Cholesterol Biosynthesis and Venous Angiogenesis

Summary UCLA researchers have identified a novel small molecule that inhibits the HMG-CoA reductase pathway, reducing cellular cholesterol and preventing vein-specific angiogenesis.Background Statins are a class of small molecule drugs used for lowering blood cholesterol levels and preventing cardiovascular disease. Atorvastatin, sold by Pfizer under...

Published: 7/19/2023 | Inventor(s):

Keywords(s):

Category(s): Therapeutics > Metabolism And Endocrinology

2008-597 A Novel Hepatic Target for Treatment of Hypercholesterolemia

Summary UCLA scientists have identified a novel regulator of cholesterol homeostasis. This regulator can be targeted for drug development to treat hypercholesterolemia and cardiac disease. Background Hypercholesterolemia, or high cholesterol, can contribute to a number of diseases, and in particular, elevated levels of low-density lipoprotein (LDL)...

Published: 7/19/2023 | Inventor(s):

Keywords(s):

Category(s): Therapeutics > Metabolism And Endocrinology

1 2 3